France to Reimburse Wegovy and Mounjaro Obesity Drugs

In a move reflecting the growing medical recognition of obesity as a chronic disease requiring therapeutic intervention, the French Health Minister announced that the state will begin reimbursing Wegovy and Mounjaro starting mid-June. According to reports, the reimbursement will officially cover 65% of the cost, potentially reaching 100% for patients with comorbidities such as diabetes or hypertension. The French government estimates the annual cost to public finances will be approximately 100 million euros.

This initiative comes as major pharmaceutical companies race to dominate the global GLP-1 market, with Eli Lilly (LLY) reporting record Mounjaro revenues of $2.3 billion in Q1 2024, per company earnings reports. Compared to peers, Novo Nordisk (NVO) has been expanding production capacity to meet surging demand for Wegovy, as France becomes the first EU nation to provide permanent reimbursement for these drugs, paving the way for government-subsidized sales growth per market data.

Regarding equity performance, Eli Lilly (LLY) closed at $815.20 and Novo Nordisk (NVO) at $132.45 (close May 28, 2026). Investors are looking ahead to the French Consumer Confidence data on May 27, 2026, which may signal purchasing power trends and the impact of new health policies. Traders are also monitoring technical support levels for NVO near $125 as a potential rebound zone in the event of a sector-wide correction.